U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)

Clinical study aims to investigate the safety and efficacy of CNP-104 in PBC patients with alkaline phosphatase (ALP) > 1.5x upper limit of normal (ULN) CHICAGO, Oct. 4, 2021 -- (Healthcare Sales & Marketing Network) -- COUR Pharmaceuticals, a biote... Biopharmaceuticals, FDA COUR Pharmaceuticals, Primary Biliary Cholangitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news